Copyright
©The Author(s) 2021.
World J Clin Cases. Jul 26, 2021; 9(21): 5812-5821
Published online Jul 26, 2021. doi: 10.12998/wjcc.v9.i21.5812
Published online Jul 26, 2021. doi: 10.12998/wjcc.v9.i21.5812
Patients characteristics | HBsAg loss (n = 11) | w/o HBsAg loss (n = 44) | P value |
Age | 35.00 (23.00-38.00) | 36.5 (28-42.75) | 0.3243 |
Gender | 10/1 | 7/37 | 0.515 |
ALT (IU/mL) | 140 (77-245) | 116 (75-219) | 0.9590 |
HBV DNA (log IU/mL) | 8.447 (6.923-8.614) | 8.024 (6.909-8.934) | 0.8844 |
Antiviral therapy (first-line/second-line)1 | 6/5 | 29/15 | 0.488 |
ADV/LAM | 4/1 | 13/2 | 0.400 |
HBsAg (log IU/mL) | 3.331 (2.826-4.582) | 3.856 (3.526-4.347) | 0.1274 |
sPD-1 (log pg/mL) | 2.766 (2.622-2.903) | 2.657 (2.540-2.765) | 0.0136 |
- Citation: Tan N, Luo H, Kang Q, Pan JL, Cheng R, Xi HL, Chen HY, Han YF, yang YP, Xu XY. Soluble programmed death-1 is predictive of hepatitis B surface antigen loss in chronic hepatitis B patients after antiviral treatment. World J Clin Cases 2021; 9(21): 5812-5821
- URL: https://www.wjgnet.com/2307-8960/full/v9/i21/5812.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v9.i21.5812